FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162255262> ?p ?o ?g. }

• W3162255262 abstract "Donor specific antibodies (DSAs) can be responsible for graft failure (GF) in the setting of mismatched hematopoietic stem cell transplantation (HSCT). The aim of our study is to report the experience of the Madrid Group of Hematopoietic Transplant (GMTH) in patients with DSAs undergoing haplo-HSCT.Patients undergoing haplo-HSCT in centers from the GMTH from 2012 to 2020 were included in the study. DSAs were analyzed with a solid-phase single-antigen immunoassay; monitoring was performed during desensitization on days -14, -7, 0 and in a weekly basis until neutrophil engraftment. Desensitization strategies varied depending on center experience, immunofluorescence intensity, complement fixation and type of antibodies.We identified a total of 20 haplo-HSCT in 19 patients performed with DSAs in 5 centers. 10 (53%) patients presented anti-HLA class I DSAs (6 of them with > 5000 mean fluorescence intensity (MFI)), 4 (21%) presented anti-HLA class II (1 with > 5000 MFI) and 5 (26%) presented both anti-HLA class I and II (5 with > 5000 MFI). 90% of patients received at least two treatments as desensitization strategy and all experienced a decrease of MFI after desensitization (mean reduction 74%). Only one patient who developed progressive increase of MFI after infusion developed GF. Desensitization treatments used included rituximab, immunoglobulins, therapeutic plasma exchange, incompatible platelets, buffy coat and immunosuppressors. Seventeen (90%) patients achieved neutrophil engraftment; one patient died before engraftment because of infection and one patient with class I DSAs developed primary GF despite an intensive desensitization. After a median follow-up of 10 months, OS and EFS were 60% and 58%, respectively, cumulative incidence of relapse was 5% and NRM was 32%.Despite the optimal strategy of DSAs desensitization remains unclear, the use of desensitization treatment guided by DSAs intensity kinetics constitute an effective approach with high rates of engraftment for patients with DSAs in need for an haplo-HSCT lacking an alternative suitable donor." @default.
• W3162255262 created "2021-05-24" @default.
• W3162255262 creator A5003788357 @default.
• W3162255262 creator A5005310970 @default.
• W3162255262 creator A5006339739 @default.
• W3162255262 creator A5010790189 @default.
• W3162255262 creator A5022715975 @default.
• W3162255262 creator A5034694882 @default.
• W3162255262 creator A5037461787 @default.
• W3162255262 creator A5042107090 @default.
• W3162255262 creator A5043047671 @default.
• W3162255262 creator A5043991937 @default.
• W3162255262 creator A5046156614 @default.
• W3162255262 creator A5050897050 @default.
• W3162255262 creator A5053626099 @default.
• W3162255262 creator A5054200855 @default.
• W3162255262 creator A5055646240 @default.
• W3162255262 creator A5061213865 @default.
• W3162255262 creator A5069457074 @default.
• W3162255262 creator A5069688502 @default.
• W3162255262 creator A5072096046 @default.
• W3162255262 creator A5083127912 @default.
• W3162255262 date "2021-05-19" @default.
• W3162255262 modified "2023-10-18" @default.
• W3162255262 title "Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant" @default.
• W3162255262 cites W1676794103 @default.
• W3162255262 cites W1977854486 @default.
• W3162255262 cites W1985742576 @default.
• W3162255262 cites W2014728570 @default.
• W3162255262 cites W2020725971 @default.
• W3162255262 cites W2039334806 @default.
• W3162255262 cites W2044762933 @default.
• W3162255262 cites W2054822629 @default.
• W3162255262 cites W2059612196 @default.
• W3162255262 cites W2064085613 @default.
• W3162255262 cites W2067831127 @default.
• W3162255262 cites W2071068942 @default.
• W3162255262 cites W2075510710 @default.
• W3162255262 cites W2078916311 @default.
• W3162255262 cites W2091645951 @default.
• W3162255262 cites W2102719248 @default.
• W3162255262 cites W2165480626 @default.
• W3162255262 cites W2167357955 @default.
• W3162255262 cites W2242834385 @default.
• W3162255262 cites W2269095736 @default.
• W3162255262 cites W2396687607 @default.
• W3162255262 cites W2559795490 @default.
• W3162255262 cites W2570187106 @default.
• W3162255262 cites W2783833392 @default.
• W3162255262 cites W2784126913 @default.
• W3162255262 cites W2786059331 @default.
• W3162255262 cites W2797446622 @default.
• W3162255262 cites W2982537460 @default.
• W3162255262 cites W3047320424 @default.
• W3162255262 cites W3082296557 @default.
• W3162255262 cites W3084268512 @default.
• W3162255262 cites W3184315968 @default.
• W3162255262 doi "https://doi.org/10.3389/fimmu.2021.674658" @default.
• W3162255262 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8170127" @default.
• W3162255262 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34093576" @default.
• W3162255262 hasPublicationYear "2021" @default.
• W3162255262 type Work @default.
• W3162255262 sameAs 3162255262 @default.
• W3162255262 citedByCount "10" @default.
• W3162255262 countsByYear W31622552622021 @default.
• W3162255262 countsByYear W31622552622022 @default.
• W3162255262 countsByYear W31622552622023 @default.
• W3162255262 crossrefType "journal-article" @default.
• W3162255262 hasAuthorship W3162255262A5003788357 @default.
• W3162255262 hasAuthorship W3162255262A5005310970 @default.
• W3162255262 hasAuthorship W3162255262A5006339739 @default.
• W3162255262 hasAuthorship W3162255262A5010790189 @default.
• W3162255262 hasAuthorship W3162255262A5022715975 @default.
• W3162255262 hasAuthorship W3162255262A5034694882 @default.
• W3162255262 hasAuthorship W3162255262A5037461787 @default.
• W3162255262 hasAuthorship W3162255262A5042107090 @default.
• W3162255262 hasAuthorship W3162255262A5043047671 @default.
• W3162255262 hasAuthorship W3162255262A5043991937 @default.
• W3162255262 hasAuthorship W3162255262A5046156614 @default.
• W3162255262 hasAuthorship W3162255262A5050897050 @default.
• W3162255262 hasAuthorship W3162255262A5053626099 @default.
• W3162255262 hasAuthorship W3162255262A5054200855 @default.
• W3162255262 hasAuthorship W3162255262A5055646240 @default.
• W3162255262 hasAuthorship W3162255262A5061213865 @default.
• W3162255262 hasAuthorship W3162255262A5069457074 @default.
• W3162255262 hasAuthorship W3162255262A5069688502 @default.
• W3162255262 hasAuthorship W3162255262A5072096046 @default.
• W3162255262 hasAuthorship W3162255262A5083127912 @default.
• W3162255262 hasBestOaLocation W31622552621 @default.
• W3162255262 hasConcept C126322002 @default.
• W3162255262 hasConcept C141071460 @default.
• W3162255262 hasConcept C159654299 @default.
• W3162255262 hasConcept C170493617 @default.
• W3162255262 hasConcept C203014093 @default.
• W3162255262 hasConcept C2777408962 @default.
• W3162255262 hasConcept C2779779143 @default.
• W3162255262 hasConcept C2780653079 @default.
• W3162255262 hasConcept C2911091166 @default.
• W3162255262 hasConcept C71924100 @default.
• W3162255262 hasConcept C90924648 @default.

• next